Taken together, ATRA has a promising therapeutic effect in the treatment of HMA‐resistant AML xenograft through re‐triggering IFN response, recapitulating the findings in cell lines and patient‐derived primary cells. Here, IFNA1 is linked to acute myeloid leukemia.